ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 501

Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis

Dilpreet Singh1, Jasdeep Badwal1, Ritika Vankina1, Santhi Gokaraju2, Jennifer Friderici3, Scott Halista4 and Tara Lagu1, 1Baystate Medical Center/Tufts University School of Medicine, Springfield, MA, 2Presbyterian Hospital of Dallas, Dallas, TX, 3Baystate Medical Center, Springfield, MA, 4Arthritis Treatment Center, Springfield, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-CCP antibodies and inflammatory arthritis, Early Rheumatoid Arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-cyclic citrullinated peptide antibody (Anti-CCP) is a diagnostic tool that predicts the progression of undifferentiated polyarthritis and erosive disease in rheumatoid arthritis (RA). It is more sensitive (60%) and specific (98%) than rheumatoid factor (RF). Despite these advantages, we hypothesize that physicians underutilize anti-CCP and other diagnostic tests for RA, which results in delay of diagnosis of RA and delay of initiation of treatment with disease modifying anti-rheumatic drugs. We aimed to describe the primary care work-up of polyarthritis in patients who eventually received a diagnosis of RA.

Methods: We performed retrospective chart review in patients seen between 1/1/2010 and 6/15/2014 in two rheumatology clinics, one private practice and one in a community health center associated with an academic medical center.

Results: We identified 173 patients seen in one of two rheumatology clinics referred from 141 different primary care providers. The sample was 83% (n=143) female, and the mean±SD age was 55.5±18.6 years. The majority (75.7%) were treated at the private practice. Anti-CCP or RF was ordered by the referring provider (prior to presentation to the rheumatologist) in only 38.7% (95% CI 31.7%, 46.3%) of patients. The presence of anti-CCP or RF did not vary significantly by presenting site: 33.3% at the community health center vs. 40.5% at the private practice, p=0.47. Ordering of anti-CCP varied non-significantly by presenting site: 19.1% of patients at the community health center presented with anti-CCP compared to 32.1% of the patients seen at the private practice (p=0.12). Prior to presentation at the rheumatology clinics, ESR was ordered in 43.9% of patients and CRP was ordered in 33.0% of patients. Ordering of ESR and/or CRP varied by site: 28.6% of patients seen at the community health center presented with ESR or CRP, but 52.7% at the private practice (p=0.008) presented with ESR or CRP. Lyme titre was ordered in 0.0% of community health center patients vs. 9.6% of private practice patients, p=0.04. Radiological imaging performed by PCP was only documented for 38.2% (n=66) of patients, with x-ray being the most frequent (46/66 or 69.7%) and MRI a distant second (6/66 or 9.1%). Functional ability was documented in only 2.3% of referred patients (95% CI 0.9%, 6.1%). About half of all patients (68, 51.1%) had DMARDS initiated immediately on presentation to the rheumatologist. Interval to treatment ranged from 0 weeks to 144, but only 18.1% (n=24) waited longer than one month for treatment. Interval to treatment was not associated with CCP order by referring physician (50% waiting > 1 month if anti-CCP was ordered vs. 30.3% if anti-CCP was not, p=0.13).

Conclusion: Most primary care physicians failed to order diagnostic tests for RA prior to referring a patient with polyarthritis to a rheumatology clinic. In particular, primary care providers failed to order anti-CCP in 61% of referred patients who eventually received a diagnosis of RA. Failure to order anti-CCP did not appear to significantly delay initiation of treatment of RA. These findings suggest educational efforts should focus on emphasizing earlier diagnostic workup, especially anti-CCP, in patients suspected to have RA.


Disclosure: D. Singh, None; J. Badwal, None; R. Vankina, None; S. Gokaraju, None; J. Friderici, None; S. Halista, None; T. Lagu, Dr. Lagu is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health. Award Number K01HL114745., 2,Dr. Lagu has received consulting fees from the Institute for Healthcare Improvement, under contract to CMS, for her work on a project to help health systems achieve disability competence., 5.

To cite this abstract in AMA style:

Singh D, Badwal J, Vankina R, Gokaraju S, Friderici J, Halista S, Lagu T. Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/use-of-rheumatologic-testing-by-primary-care-physicians-in-patients-with-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-rheumatologic-testing-by-primary-care-physicians-in-patients-with-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology